Orasure Technologies (OSUR) AI Stock Analysis

Compare

642 Followers

Top Page

Orasure Technologies

(NASDAQ:OSUR)

Rating:57Neutral

Price Target:

$3.50

▲(0.57% Upside)

Orasure Technologies' overall stock score is primarily impacted by financial challenges, including declining revenues and profitability. While technical indicators show some short-term bullish momentum, valuation concerns due to negative earnings and the absence of dividends weigh heavily. The earnings call provided mixed insights, with some positive developments overshadowed by significant challenges.

Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$229.65M

Dividend YieldN/A

Average Volume (3M)637.86K

Price to Earnings (P/E)25.3

Beta (1Y)0.77

Revenue Growth-49.35%

EPS Growth-285.61%

CountryUS

Employees501

SectorHealthcare

Sector Strength45

IndustryMedical - Instruments & Supplies

Share Statistics

EPS (TTM)-0.26

Shares Outstanding73,136,986

10 Day Avg. Volume401,391

30 Day Avg. Volume637,855

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)0.65

Price to Sales (P/S)1.45

P/FCF Ratio11.40

Enterprise Value/Market Cap0.01

Enterprise Value/Revenue0.08

Enterprise Value/Gross Profit0.07

Enterprise Value/Ebitda-0.10

Forecast

1Y Price Target

$3.50

Price Target Upside0.57% Upside

Rating ConsensusHold

Number of Analyst Covering1

Orasure Technologies Business Overview & Revenue Model

Company DescriptionOrasure Technologies, Inc. is a leading provider of oral fluid diagnostic products, specializing in the development, manufacture, and marketing of innovative medical devices and testing solutions. The company primarily operates in the healthcare sector, focusing on infectious disease testing, drug testing, and molecular diagnostics. Its core products include the OraQuick® rapid HIV test and the Intercept® oral fluid collection device, which are designed for ease of use and accuracy in various clinical and non-clinical settings.

How the Company Makes MoneyOrasure Technologies generates revenue primarily through the sale of its diagnostic products and testing services. Key revenue streams include the sale of rapid testing kits for infectious diseases and drug abuse, which are marketed to healthcare providers, laboratories, and government agencies. The company also earns income from licensing agreements and collaborations with other organizations to develop new testing technologies. Significant partnerships with public health organizations and collaborations with research institutions enhance its market reach and contribute to its earnings. Additionally, Orasure may benefit from government contracts and grants aimed at improving public health outcomes through innovative diagnostic solutions.

Orasure Technologies Earnings Call Summary

Earnings Call Date:Aug 05, 2025

(Q2-2025)

% Change Since: |

Next Earnings Date:Nov 05, 2025

Earnings Call Sentiment Neutral

The earnings call presented several highlights, including the successful launch of the HEMAcollect PROTEIN product and a strong cash position. However, these were offset by significant challenges, such as disruptions in international diagnostics and a decline in Sample Management revenue. The uncertainty in U.S. Diagnostics further balanced the positive developments.

Q2-2025 Updates

Positive Updates

Successful Launch of HEMAcollect PROTEIN

In July, OTI launched HEMAcollect PROTEIN, which expands their Sample Management Solutions into a new sample type, blood. This product advances proteomic research by offering extended protein stabilization at room temperature and simplified workflows.

Strong Financial Position

OTI ended Q2 with $235 million in cash and cash equivalents and no debt, allowing them to continue investments in innovative products like Sherlock and Colli-Pee.

Renewal Agreement with GeneDx

OTI renewed their agreement with GeneDx, a long-standing customer, to support early diagnosis of rare pediatric diseases using their ORAcollect kits.

Negative Updates

Challenges in International Diagnostics

Despite year-over-year growth, international diagnostics faced disruptions due to USAID funding freezes, affecting the deployment pace of HIV tests.

Decline in Sample Management Revenue

Sample Management revenue decreased 22% year-over-year, primarily due to a large customer in the Consumer Genetics segment, impacting overall core revenue growth.

Uncertainty in U.S. Diagnostics Revenue

U.S. Diagnostics revenue declined 1% year-over-year, with uncertainty arising from potential cuts to public health program budgets and staffing reductions in key health agencies.

Company Guidance

In the OraSure Technologies Second Quarter 2025 Earnings Conference Call, the company reported total revenue of $31.2 million, with core revenue at $30.8 million, surpassing the midpoint of their guidance. The diagnostics segment grew by 3% year-over-year, while Sample Management revenue decreased by 22% due to a decline in orders from a major consumer genetics customer. Excluding this impact, Sample Management revenue would have shown positive growth. The international diagnostics business experienced year-over-year growth despite disruptions caused by USAID funding freezes, impacting the pace of HIV test deployments. The U.S. diagnostics revenue remained steady, declining just 1% year-over-year, influenced by potential public health program budget cuts. The company also highlighted the successful transition of manufacturing operations to Pennsylvania, completed ahead of schedule, and the launch of the HEMAcollect PROTEIN offering to support proteomic research. Looking ahead, OraSure guides for third-quarter revenue between $27 million and $30 million, with expectations of a slower pace of international orders and reduced revenue from the Together Take Me Home program.

Orasure Technologies Financial Statement Overview

Summary

Orasure Technologies faces financial challenges with declining revenues and profitability, as evidenced by a net loss and negative EBIT and EBITDA margins. Despite a strong balance sheet with low leverage, negative profitability and cash flow issues highlight operational inefficiencies.

Income Statement

Neutral

Orasure Technologies has faced challenges in its income statement with declining revenues and profitability. The TTM (Trailing-Twelve-Months) shows a net loss with negative EBIT and EBITDA margins, indicating operational inefficiencies. Revenue growth has been erratic, with recent declines, suggesting volatility in sales performance.

Balance Sheet

Positive

The balance sheet of Orasure Technologies is relatively strong, with a high equity ratio and low debt levels. The company's debt-to-equity ratio is low, implying low financial leverage and risk. However, despite strong equity, the return on equity is negative, highlighting the impact of ongoing losses.

Cash Flow

Neutral

Cash flow analysis reveals a mixed picture. The company has generated positive operating cash flow in the TTM, but free cash flow has turned negative due to capital expenditures. The free cash flow to net income ratio indicates challenges in converting earnings to cash, suggesting operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.67M	185.83M	405.47M	387.48M	233.67M	171.72M
Gross Profit	43.19M	79.39M	179.42M	147.64M	117.60M	101.87M
EBITDA	-31.43M	-5.13M	64.35M	10.29M	9.00K	3.44M
Net Income	-51.03M	-19.50M	53.66M	-17.93M	-23.00M	-14.92M
Balance Sheet
Total Assets	445.04K	479.66M	482.85M	444.71M	460.99M	454.47M
Cash, Cash Equivalents and Short-Term Investments	234.58K	267.76M	290.41M	110.85M	153.04M	209.40M
Total Debt	0.00	14.60M	13.50M	12.55M	12.27M	6.13M
Total Liabilities	64.31M	69.32M	52.17M	81.08M	80.46M	55.90M
Stockholders Equity	380.72M	410.34M	430.67M	363.62M	380.53M	398.57M
Cash Flow
Free Cash Flow	12.16M	23.58M	131.28M	-111.11M	-83.50M	-23.12M
Operating Cash Flow	12.76M	27.37M	141.58M	-47.20M	-35.38M	5.81M
Investing Cash Flow	273.00K	-39.03M	66.15M	21.09M	-5.50M	-14.03M
Financing Cash Flow	-7.59M	-4.18M	-3.02M	-3.83M	-2.82M	92.48M

Orasure Technologies Technical Analysis

Technical Analysis Sentiment

Positive

Last Price3.48

Price Trends

50DMA

3.04

Positive

100DMA

2.95

Positive

200DMA

3.35

Positive

Market Momentum

MACD

0.01

Negative

RSI

70.27

Negative

STOCH

93.54

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Positive. The current price of 3.48 is above the 20-day moving average (MA) of 2.95, above the 50-day MA of 3.04, and above the 200-day MA of 3.35, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 70.27 is Negative, neither overbought nor oversold. The STOCH value of 93.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSUR.

Orasure Technologies Risk Analysis

Orasure Technologies disclosed 67 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Orasure Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	77 Outperform	$194.72M	16.14	10.39%	2.00%	-16.64%	-13.64%
PDEX	75 Outperform	$152.32M	16.69	28.29%	―	29.65%	131.78%
STXS	66 Neutral	$250.20M	―	-198.62%	―	33.94%	-6.91%
KRMD	59 Neutral	$194.19M	―	-25.63%	―	19.57%	61.81%
SMTI	58 Neutral	$293.15M	―	-25.78%	―	34.29%	-49.21%
OSUR	57 Neutral	$229.65M	25.27	-12.65%	―	-49.35%	-285.61%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%

* Healthcare Sector Average

Performance Comparison

OSUR

Orasure Technologies

3.48

-0.87

-20.00%

PDEX

Pro-Dex

46.71

24.73

112.51%

STXS

Stereotaxis

2.78

0.56

25.23%

UTMD

Utah Medical Products

60.74

-6.16

-9.21%

KRMD

REPRO-MED Systems

4.26

1.82

74.59%

SMTI

Sanara MedTech

33.65

-0.50

-1.46%

Orasure Technologies Corporate Events

Business Operations and StrategyFinancial Disclosures

OraSure Technologies Reports 43% Revenue Decline in Q2 2025

Negative

Aug 5, 2025

On August 5, 2025, OraSure Technologies announced its financial results for the quarter ended June 30, 2025. The company reported a decrease in total net revenues by 43% compared to the same period in 2024, with significant declines in molecular services and COVID-19 related revenues. Despite the revenue drop, OraSure is focused on expanding its product portfolio and commercial reach, with plans to launch new products and leverage its strong balance sheet for future growth.

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 27, 2025